SUPLEXA cell immunotherapy (Alloplex Biotherapeutics)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameSUPLEXA cell immunotherapy (Alloplex Biotherapeutics)

Drug Alias NamePBMC-derived autologous cellular therapyAutologous cellular therapy comprised predominantly of NK, NK-T, and T cells stored in cryogenic media

ClassificationCell and gene therapy > Cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAlloplex Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAlloplex Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A